ERBB2 and breast carcinoma: In a retrospective study of patients with T1-T2N0, HER2+ breast cancer, Kiess et al[13] reported a marked difference in 3-year LRR rate with and without adjuvant trastuzumab (10% vs 1%) following adjuvant whole breast RT.